ClinicalTrials.gg
RecruitingNCT06500234Updated Jul 15, 2024

Nutrition Impact on Immunotherapy of Cancer

A Phase 3 interventional study of Megestrol Acetate and olanzapine and Starch powder 50 mg in Nutrition Disorders, Immunotherapy and Cancer, sponsored by Qingdao Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Qingdao Central Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study investigates nutritional status and outcomes of immuntherapy in cancer patients.

Read the detailed description

Studies have shown that more than half of the patients with cancer are also malnourished at diagnosis. This increases patients' risk of complications associated with the treatment as well as the abandonment of care, as well as decrease the level of survival rates.

02

Conditions studied

  • Nutrition Disorders
  • Immunotherapy
  • Cancer
  • Survival, Prosthesis
03

In context

Nutrition Disorders

233 studies on the registry are indexed under Nutrition Disorders; 26 are open to participants now.

This study's planned enrollment of 300 is above the median of 105 across 169 interventional studies indexed under Nutrition Disorders.

Browse Nutrition Disorders studies →

Lead sponsor

Qingdao Central Hospital is the lead sponsor of 24 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of cancer, malnutrition Age >18 years Performance status of 0 or 2. ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type ( v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment or evidence of non-childbearing status for women of Patient is willing and able to comply with the protocol for the duration of the study.

For all oral medications patients must be able to comfortably swallow capsules;

Exclusion criteria

Exclusion Criteria:

  • Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation.

Active or prior documented or inflammatory disorders Uncontrolled intercurrent illness or patient considered a poor medical risk due to a serious, uncontrolled medical disorder, including but not limited to, ongoing or active infection, symptomatic congestive heart failure Currently taking medications with known risk of prolonging the or inducing Torsades de Pointes.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    megestrol acetate-olanzapine

    Megestrol acetate 160 mg, oral, everyday Olanzapine 2.5 mg, oral everyday

    Drug: Megestrol Acetate and olanzapine

  • Placebo comparator
    control

    Starch powder 50 mg, oral, everyday,

    Drug: Starch powder 50 mg

Interventions

  • DrugMegestrol Acetate and olanzapine

    Drug pages: Megestrol Acetate · Olanzapine

    megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday

  • DrugStarch powder 50 mg

    Starch powder 50 mg, oral, everyday

06

What researchers measure

Primary outcomes

  1. ORR

    overall response rate

    Time frame: 12 months

Secondary outcomes

  1. PFS

    profression-free survival

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for May 2025, 11 months after the start.

Of 25 phase 3 interventional studies under Nutrition Disorders, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 28. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Jul 15, 2024
StartActual
Jun 1, 2024
Primary completionEst.
May 31, 2025
CompletionEst.
May 31, 2027
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06500234
Lead sponsor
Qingdao Central Hospital
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jun 1, 2024
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jul 15, 2024

Study contacts

Keke Nie, MD
Contact
niekeke@uor.edu.cn
53268665078
chunling zhang, MD
study chair · Qingdao Central Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Megestrol Acetate · Olanzapine

Start the discussion